EU DECLARATION OF CONFORMITY (DoC)

Manufacturer:	Becton Dickinson Infusion Therapy Systems Inc., 9450 South State Street, Sandy, Utah 84070, USA
Manufacturer SRN:	US-MF-000017719
Authorised Representative:	Becton Dickinson Ireland Ltd. Donore Road, Drogheda, Co. Louth A92 YW26, Ireland
Authorised Representative SRN:	IE-AR-000007610
Product:	BD Insyte™ Autoguard™ Shielded IV Catheters BD Insyte™ Autoguard™ BC Pro Shielded IV Catheters
Basic UDI-DI:	038290KCPPHCMV8Y 038290TFYRGYXIPP 038290FYLKFOEMEG 038290HDSBCRGE3R 038290HDCOZIJX6T 038290OAODRZZNC9
Risk Class and Rule:	Class IIa, Annex VIII, Rule 7
Intended Purpose	BD Insyte™ Autoguard™ shielded IV catheters are intended to be inserted into a patient's peripheral vascular system for short term use to sample blood, monitor blood pressure, or administer fluids. These devices may be used for any patient population with consideration given to adequacy of vascular anatomy, procedure being performed, fluids being infused, and duration of therapy. The 22-18 GA (0.9-1.3 mm) devices are suitable for use with power injectors set to a maximum pressure of 300 psi (2068 kPa). BD Insyte™ Autoguard™ BC Pro shielded IV catheters are intended to be inserted into a patient's peripheral vascular system for short term use to sample blood, monitor blood pressure, or administer fluids. These devices may be used for any patient population with consideration given to adequacy of vascular anatomy, procedure being performed, fluids being infused, and duration of therapy. The 22-18 GA (0.9-1.3 mm) devices are suitable for use with power injectors set to a maximum pressure of 300 psi (2068 kPa).
Notified Body:	BSI Say Building, John M. Keynesplein 9, 1066 EP Amsterdam, The Netherlands Notified Body Number: 2797

We, as the manufacturer of the device(s) take sole responsibility for and hereby declare that the above-mentioned product(s) meet(s) the provisions of the following Directives/ Regulation(s):

- Regulation (EU) 2017/745 of the European Parliament and of the Council on Medical Devices

Conformity Assessment Route:

☒ ANNEX IX Chapter I and III – Quality management System	EC CERTIFICATE No.: MDR 731353
☐ ANNEX IX Chapter II - Technical Documentation	EC CERTIFICATE No.:
☐ ANNEX X Type Examination	EC CERTIFICATE No.:
☐ ANNEX XI Part A Production Quality Assurance	EC CERTIFICATE No.:
☐ ANNEX XI Part B Product Verification	EC CERTIFICATE No.:
☐ ANNEX II & III Technical Documentation	N/A

Common Specifications (CS):

Number: <Version/Year>	**Title:**	**Full or Partial Application:** <Justification>
N/A	N/A	N/A

Devices Covered by this DoC: *<only complete if more than one device is covered by this DoC>*

SKU#	Device Name	Device Class
381811	BD Insyte-N™ Autoguard™ Shielded IV Catheter	Class IIa
381812	BD Insyte™ Autoguard™ Shielded IV Catheter	Class IIa
381823	BD Insyte™ Autoguard™ Shielded IV Catheter	Class IIa
381833	BD Insyte™ Autoguard™ Shielded IV Catheter	Class IIa
381834	BD Insyte™ Autoguard™ Shielded IV Catheter	Class IIa
381837	BD Insyte™ Autoguard™ Shielded IV Catheter	Class IIa
381844	BD Insyte™ Autoguard™ Shielded IV Catheter	Class IIa
381847	BD Insyte™ Autoguard™ Shielded IV Catheter	Class IIa
381854	BD Insyte™ Autoguard™ Shielded IV Catheter	Class IIa
381857	BD Insyte™ Autoguard™ Shielded IV Catheter	Class IIa
381867	BD Insyte™ Autoguard™ Shielded IV Catheter	Class IIa
381911	BD Insyte-N™ Autoguard™ Winged Shielded IV Catheter	Class IIa
381912	BD Insyte™ Autoguard™ Winged Shielded IV Catheter	Class IIa

381923	BD Insyte™ Autoguard™ Winged Shielded IV Catheter	Class IIa
381933	BD Insyte™ Autoguard™ Winged Shielded IV Catheter	Class IIa
381934	BD Insyte™ Autoguard™ Winged Shielded IV Catheter	Class IIa
381937	BD Insyte™ Autoguard™ Winged Shielded IV Catheter	Class IIa
381944	BD Insyte™ Autoguard™ Winged Shielded IV Catheter	Class IIa
381947	BD Insyte™ Autoguard™ Winged Shielded IV Catheter	Class IIa
381954	BD Insyte™ Autoguard™ Winged Shielded IV Catheter	Class IIa
381957	BD Insyte™ Autoguard™ Winged Shielded IV Catheter	Class IIa
381012	BD Insyte™ Autoguard™ BC Pro Shielded IV Catheter	Class IIa
381023	BD Insyte™ Autoguard™ BC Pro Shielded IV Catheter	Class IIa
381033	BD Insyte™ Autoguard™ BC Pro Shielded IV Catheter	Class IIa
381034	BD Insyte™ Autoguard™ BC Pro Shielded IV Catheter	Class IIa
381037	BD Insyte™ Autoguard™ BC Pro Shielded IV Catheter	Class IIa
381044	BD Insyte™ Autoguard™ BC Pro Shielded IV Catheter	Class IIa
381047	BD Insyte™ Autoguard™ BC Pro Shielded IV Catheter	Class IIa
381054	BD Insyte™ Autoguard™ BC Pro Shielded IV Catheter	Class IIa
381057	BD Insyte™ Autoguard™ BC Pro Shielded IV Catheter	Class IIa
382912	BD Insyte™ Autoguard™ BC Pro Winged Shielded IV Catheter	Class IIa
382923	BD Insyte™ Autoguard™ BC Pro Winged Shielded IV Catheter	Class IIa
382933	BD Insyte™ Autoguard™ BC Pro Winged Shielded IV Catheter	Class IIa
382934	BD Insyte™ Autoguard™ BC Pro Winged Shielded IV Catheter	Class IIa
382937	BD Insyte™ Autoguard™ BC Pro Winged Shielded IV Catheter	Class IIa
382944	BD Insyte™ Autoguard™ BC Pro Winged Shielded IV Catheter	Class IIa
382947	BD Insyte™ Autoguard™ BC Pro Winged Shielded IV Catheter	Class IIa
382954	BD Insyte™ Autoguard™ BC Pro Winged Shielded IV Catheter	Class IIa
382957	BD Insyte™ Autoguard™ BC Pro Winged Shielded IV Catheter	Class IIa

Document: PIV-STED-003-DOC
Valid From: 03-Mar-2025 To: 31-Dec-9999
Print Date: 12-Mar-2025 08:00:35 GMT Standard Time
Doc Type: ZRF
Doc Part: EN
Usage: Production Usage
Status: Released EFFECTIVE
Revision: N/A
Version: D
Change #: N/A
Classification: Confidential

Obsolete Products

REF	Description	Last Lot Number	Mfg Date	Exp Date
381024	BD Insyte™ Autoguard™ BC Pro Shielded IV Catheter	2046632	1-Feb-2022	31-Jan-2025
382924	BD Insyte™ Autoguard™ BC Pro Winged Shielded IV Catheter	336098	1-Dec-2020	30-Nov-2023

† No longer manufactured with the CE mark. The existing inventory will continue to be sold until depletion; at which time the product will be sold without the CE mark to territories where product is registered.

Authorised Signatory:	
Name & Title:	Christopher Rogers, VP Regulatory Affairs
On behalf of:	Becton Dickinson Infusion Therapy Systems Inc.
Place of Issue:	9450 South State Street, Sandy, Utah 84070, USA
Date of Issue:	26-Feb-2025
Signature:	Signed by: Christopher Rogers Signer Name: Christopher Rogers Signing Reason: I approve this document Signing Time: 26-Feb-2025 | 12:08:00 PM PST 36DFBDC7D93A4EDD8A95BFA0996E41F6

DECLARATION OF CONFORMITY Revision History:

Version:	Detailed Change Description:
A	Original Release
B	Updated to Revision 06 of DoC template (CBI-058 FRM20)
C	Corrected conformity assessment route (removing MDR certificate and unselecting Annex IX Chapter II). Remove references to Regulation (EU) 207/2012 on electronic instructions for use of medical devices
D	Removal of SKU's (381024 and 382924); Added obsolete table and skus (381024 and 382924) to the table along with last lot number, manufacturing date, and expiration date.

TEMPLATE Revision History:

Rev	Revision Description	ECO Number	Requested By
06	Removed Certificate Expiration Date from Conformity Assessment Route section of the DoC. This is not required by 2017/745 and does not impact conformity assessment requirements. Modified European Authorized Representative Example in instructions from BD Switzerland to BD Ireland Limited.	500000325481	David Pieratos
05	Updated Authorized Signatory section to include a box with the statement “On behalf of” as well as provide guidance/instructions. This requirement MDR requirement for the DoC was missed in the Revision 4 update.	500000285045	Terri Krutz
04	Updated to include Chapter III in conformity assessment route option “ANNEX IX Chapter I – Quality management System” for all languages. Modified header to include Version Number as some businesses use SAP and others may use other approval and storage systems	500000283041	C. Pell
03	Updated to include Intended Purpose and guidance. Updated Revision History in Footer.	500000230219	David Pieratos
02	Based on recommendations from the BDX European Regulatory Affairs team, the DoC was reformatted to simplify the content to be in line with 2017/745 and MedTech Europe Guidance.	500000213116	Denise Oliveira
01	Original release.	500000190393	Jennifer Jaye

Certificate Of Completion

Envelope Id: D76442CE-3FBD-4F47-B422-722C56797CB5
Status: Completed
Subject: Complete with Docusign: PIV-STED-003-DOC_Rev. D.docx
Source Envelope:
Document Pages: 5
Signatures: 1
Certificate Pages: 5
Initials: 0
AutoNav: Enabled
EnvelopeId Stamping: Disabled
Time Zone: (UTC-08:00) Pacific Time (US & Canada)

Envelope Originator:
Sunny Patel
1 Becton Drive
Franklin Lakes, NJ 07417
Sunny.Patel@bd.com
IP Address: 204.193.36.5

Record Tracking

Status: Original
2/26/2025 10:05:29 AM
Holder: Sunny Patel
Sunny.Patel@bd.com
Location: DocuSign

Signer Events	Signature	Timestamp
Christopher Rogers Christopher.Rogers2@bd.com VP Regulatory Affairs Security Level: Email, Account Authentication (Required)	Christopher Rogers Signature Adoption: Pre-selected Style Signature ID: 36DFBDC7-D93A-4EDD-8A95-BFA0996E41F6 Using IP Address: 63.106.106.2 With Signing Authentication via Docusign password With Signing Reasons (on each tab): I approve this document	Sent: 2/26/2025 10:07:11 AM Viewed: 2/26/2025 12:06:56 PM Signed: 2/26/2025 12:08:25 PM
Electronic Record and Signature Disclosure: Accepted: 10/30/2023 11:08:51 AM ID: fd6a20fb-6d76-4978-bb25-98f4f102aa40		

In Person Signer Events	Signature	Timestamp

Editor Delivery Events	Status	Timestamp

Agent Delivery Events	Status	Timestamp

Intermediary Delivery Events	Status	Timestamp

Certified Delivery Events	Status	Timestamp

Carbon Copy Events	Status	Timestamp

Witness Events	Signature	Timestamp

Notary Events	Signature	Timestamp

Envelope Summary Events	Status	Timestamps
Envelope Sent	Hashed/Encrypted	2/26/2025 10:07:11 AM
Certified Delivered	Security Checked	2/26/2025 12:06:56 PM
Signing Complete	Security Checked	2/26/2025 12:08:25 PM
Completed	Security Checked	2/26/2025 12:08:25 PM

Payment Events	Status	Timestamps

Electronic Record and Signature Disclosure

ELECTRONIC RECORD AND SIGNATURE DISCLOSURE

From time to time, Becton Dickinson - Quality/Regulatory Affairs (P11) (we, us or Company) may be required by law to provide to you certain written notices or disclosures. Described below are the terms and conditions for providing to you such notices and disclosures electronically through the DocuSign system. Please read the information below carefully and thoroughly, and if you can access this information electronically to your satisfaction and agree to this Electronic Record and Signature Disclosure (ERSD), please confirm your agreement by selecting the check-box next to 'I agree to use electronic records and signatures' before clicking 'CONTINUE' within the DocuSign system.

Getting paper copies

At any time, you may request from us a paper copy of any record provided or made available electronically to you by us. You will have the ability to download and print documents we send to you through the DocuSign system during and immediately after the signing session and, if you elect to create a DocuSign account, you may access the documents for a limited period of time (usually 30 days) after such documents are first sent to you. After such time, if you wish for us to send you paper copies of any such documents from our office to you, you will be charged a $0.00 per-page fee. You may request delivery of such paper copies from us by following the procedure described below.

Withdrawing your consent

If you decide to receive notices and disclosures from us electronically, you may at any time change your mind and tell us that thereafter you want to receive required notices and disclosures only in paper format. How you must inform us of your decision to receive future notices and disclosure in paper format and withdraw your consent to receive notices and disclosures electronically is described below.

Consequences of changing your mind

If you elect to receive required notices and disclosures only in paper format, it will slow the speed at which we can complete certain steps in transactions with you and delivering services to you because we will need first to send the required notices or disclosures to you in paper format, and then wait until we receive back from you your acknowledgment of your receipt of such paper notices or disclosures. Further, you will no longer be able to use the DocuSign system to receive required notices and consents electronically from us or to sign electronically documents from us.

All notices and disclosures will be sent to you electronically

Unless you tell us otherwise in accordance with the procedures described herein, we will provide electronically to you through the DocuSign system all required notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you during the course of our relationship with you. To reduce the chance of you inadvertently not receiving any notice or disclosure, we prefer to provide all of the required notices and disclosures to you by the same method and to the same address that you have given us. Thus, you can receive all the disclosures and notices electronically or in paper format through the paper mail delivery system. If you do not agree with this process, please let us know as described below. Please also see the paragraph immediately above that describes the consequences of your electing not to receive delivery of the notices and disclosures electronically from us.

How to contact Becton Dickinson - Quality/Regulatory Affairs (P11):

You may contact us to let us know of your changes as to how we may contact you electronically, to request paper copies of certain information from us, and to withdraw your prior consent to receive notices and disclosures electronically as follows:
To contact us by email send messages to: leonardo_m_hoto@bd.com

To advise Becton Dickinson - Quality/Regulatory Affairs (P11) of your new email address

To let us know of a change in your email address where we should send notices and disclosures electronically to you, you must send an email message to us at leonardo_m_hoto@bd.com and in the body of such request you must state: your previous email address, your new email address. We do not require any other information from you to change your email address.

If you created a DocuSign account, you may update it with your new email address through your account preferences.

To request paper copies from Becton Dickinson - Quality/Regulatory Affairs (P11)

To request delivery from us of paper copies of the notices and disclosures previously provided by us to you electronically, you must send us an email to leonardo_m_hoto@bd.com and in the body of such request you must state your email address, full name, mailing address, and telephone number. We will bill you for any fees at that time, if any.

To withdraw your consent with Becton Dickinson - Quality/Regulatory Affairs (P11)

To inform us that you no longer wish to receive future notices and disclosures in electronic format you may:

i. decline to sign a document from within your signing session, and on the subsequent page, select the check-box indicating you wish to withdraw your consent, or you may;

ii. send us an email to leonardo_m_hoto@bd.com and in the body of such request you must state your email, full name, mailing address, and telephone number. We do not need any other information from you to withdraw consent.. The consequences of your withdrawing consent for online documents will be that transactions may take a longer time to process..

Required hardware and software

The minimum system requirements for using the DocuSign system may change over time. The current system requirements are found here: https://support.docusign.com/guides/signer-guide-signing-system-requirements.

Acknowledging your access and consent to receive and sign documents electronically

To confirm to us that you can access this information electronically, which will be similar to other electronic notices and disclosures that we will provide to you, please confirm that you have read this ERSD, and (i) that you are able to print on paper or electronically save this ERSD for your future reference and access; or (ii) that you are able to email this ERSD to an email address where you will be able to print on paper or save it for your future reference and access. Further, if you consent to receiving notices and disclosures exclusively in electronic format as described herein, then select the check-box next to 'I agree to use electronic records and signatures' before clicking 'CONTINUE' within the DocuSign system.

By selecting the check-box next to 'I agree to use electronic records and signatures', you confirm that:

- You can access and read this Electronic Record and Signature Disclosure; and
- You can print on paper this Electronic Record and Signature Disclosure, or save or send this Electronic Record and Disclosure to a location where you can print it, for future reference and access; and
- Until or unless you notify Becton Dickinson - Quality/Regulatory Affairs (P11) as described above, you consent to receive exclusively through electronic means all notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you by Becton Dickinson - Quality/Regulatory Affairs (P11) during the course of your relationship with Becton Dickinson - Quality/Regulatory Affairs (P11).